{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T03:02:19Z","timestamp":1776567739742,"version":"3.51.2"},"reference-count":56,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2016,6,23]],"date-time":"2016-06-23T00:00:00Z","timestamp":1466640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Respir Dis"],"published-print":{"date-parts":[[2016,8]]},"abstract":"<jats:p> Telavancin (TLV) is a lipoglycopeptide derivative of vancomycin (VAN), which has activity against Gram-positive aerobic bacteria, and is especially effective against methicillin-resistant Staphylococcus aureus (MRSA) and Gram-positive bacteria resistant to VAN. Comparative clinical studies of TLV have demonstrated noninferiority compared with VAN in the treatment of hospital-acquired Gram-positive pneumonia, with high cure rates for TLV-treated patients with monomicrobial S. aureus infection, including isolates with reduced VAN susceptibility. The results based on the patients\u2019 clinical response were supported by supplemental post-hoc analyses of 28-day mortality. In Europe and the USA, TLV is approved as a useful alternative for patients with difficult-to-treat, hospital-acquired MRSA pneumonia when there are very few alternatives. The present article reviews TLV\u2019s pharmacological characteristics and clinical efficacy resulting from clinical trials giving a detailed picture of its properties and position in the management of hospital-acquired pneumonia. <\/jats:p>","DOI":"10.1177\/1753465816651594","type":"journal-article","created":{"date-parts":[[2016,6,24]],"date-time":"2016-06-24T01:13:39Z","timestamp":1466730819000},"page":"368-378","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Telavancin in the treatment of <i>Staphylococcus aureus<\/i> hospital-acquired and ventilator-associated pneumonia: clinical evidence and experience"],"prefix":"10.1177","volume":"10","author":[{"given":"Adamantia","family":"Liapikou","sequence":"first","affiliation":[{"name":"6th Respiratory Department, Sotiria Hospital, Mesogion 152, 11527, Athens"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katerina","family":"Dimakou","sequence":"additional","affiliation":[{"name":"5th Respiratory Department, Sotiria Hospital, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Toumbis","sequence":"additional","affiliation":[{"name":"6th Respiratory Department, Sotiria Hospital, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2016,6,23]]},"reference":[{"key":"bibr1-1753465816651594","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200405-644ST"},{"key":"bibr2-1753465816651594","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0b013e32835f27be"},{"key":"bibr3-1753465816651594","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl424"},{"key":"bibr4-1753465816651594","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.15.53"},{"key":"bibr5-1753465816651594","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12450"},{"key":"bibr6-1753465816651594","unstructured":"Clinigen Healthcare Ltd (2014) Vibativ: Summary of Product Characteristics. Burton upon Trent: Clinigen Healthcare Ltd. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/001240\/human_med_001467.jsp&mid=WC0b01ac058001d124"},{"key":"bibr7-1753465816651594","unstructured":"Clinigen Specialty Pharmaceuticals (2014) Direct Healthcare Professional Communication on the Launch of Vibativ\u00ae (Telavancin): Recommendations for Use and Important Risks (Nephrotoxicity, QTc Prolongation, Reproductive Toxicity and Off-label Use). Burton upon Trent: Clinigen Specialty Pharmaceuticals. http:\/\/www.mhra.gov.uk\/home\/groups\/commsic\/documents\/drugsafetymessage\/con428392.pdf (accessed 30 November 2014)."},{"key":"bibr8-1753465816651594","volume-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically Approved Standard M07-A9","author":"CLSI","year":"2012"},{"key":"bibr9-1753465816651594","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02330-13"},{"key":"bibr10-1753465816651594","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu971"},{"key":"bibr11-1753465816651594","unstructured":"EMA (2011) EPAR Summary for the Public. Vibativ, Telavancin. London: European Medicines Agency. http:\/\/www.vibativ.eu\/latest_news\/new-drug-approvals-europeema-2011-a-knol-by-krishan-maggon\/"},{"key":"bibr12-1753465816651594","unstructured":"FDA (2012) Advisory Committee Briefing Document Telavancin for Nosocomial Pneumonia. Anti-Infective Drugs Advisory Committee Meeting. Silver Spring, MA: US Food and Drug Administration. http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/Anti-InfectiveDrugsAdvisoryCommittee\/UCM329482.pdf (accessed 3 January 2015)."},{"key":"bibr13-1753465816651594","unstructured":"FDA (2014a) Highlights of Prescribing Information. Revised February 2014. Silver Spring, MA: US Food and Drug Administration. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/022110s007lbl.pdf (accessed 15 July 2014)."},{"key":"bibr14-1753465816651594","unstructured":"FDA (2014b) Guidance for Industry. Hospital-acquired Bacterial Pneumonia and Ventilator Associated Bacterial Pneumonia: Developing Drugs for Treatment. Draft Guidance. Silver Spring, MA: US Food and Drug Administration. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM234907.pdf (accessed 9 March 2015)."},{"key":"bibr15-1753465816651594","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00908-08"},{"key":"bibr16-1753465816651594","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki198"},{"key":"bibr17-1753465816651594","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00875-07"},{"key":"bibr18-1753465816651594","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.3.1127-1134.2005"},{"key":"bibr19-1753465816651594","doi-asserted-by":"publisher","DOI":"10.7883\/yoken.JJID.2014.282"},{"key":"bibr20-1753465816651594","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00100-07"},{"key":"bibr21-1753465816651594","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ534"},{"key":"bibr22-1753465816651594","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00742-09"},{"key":"bibr23-1753465816651594","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01642-08"},{"key":"bibr24-1753465816651594","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02127-12"},{"key":"bibr25-1753465816651594","doi-asserted-by":"publisher","DOI":"10.1086\/678594"},{"key":"bibr26-1753465816651594","first-page":"939","author":"Liapikou A.","year":"2012","journal-title":"Future Science"},{"key":"bibr27-1753465816651594","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01143-09"},{"key":"bibr28-1753465816651594","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01110-07"},{"key":"bibr29-1753465816651594","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01609-09"},{"key":"bibr30-1753465816651594","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00933-10"},{"key":"bibr31-1753465816651594","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.12.006"},{"key":"bibr32-1753465816651594","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2014.12.011"},{"key":"bibr33-1753465816651594","author":"Mendes R.","year":"2015","journal-title":"J Chemother"},{"key":"bibr34-1753465816651594","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00011-12"},{"key":"bibr35-1753465816651594","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04616-14"},{"key":"bibr36-1753465816651594","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.9.12.2197"},{"key":"bibr37-1753465816651594","volume-title":"Evidence Summary: New Medicine. Hospital-acquired Pneumonia Caused by Methicillin Resistant Staphylococcus aureus: Telavancin","author":"NICE","year":"2014"},{"key":"bibr38-1753465816651594","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01470-06"},{"key":"bibr39-1753465816651594","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq335"},{"key":"bibr40-1753465816651594","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01210-14"},{"key":"bibr41-1753465816651594","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq031"},{"key":"bibr42-1753465816651594","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S25930"},{"key":"bibr43-1753465816651594","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05915-11"},{"key":"bibr44-1753465816651594","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.757"},{"key":"bibr45-1753465816651594","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ535"},{"key":"bibr46-1753465816651594","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm211"},{"key":"bibr47-1753465816651594","doi-asserted-by":"publisher","DOI":"10.1086\/499815"},{"key":"bibr48-1753465816651594","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.1.195-201.2005"},{"key":"bibr49-1753465816651594","doi-asserted-by":"publisher","DOI":"10.1097\/SHK.0b013e3181cc0418"},{"key":"bibr50-1753465816651594","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2013.06.003"},{"key":"bibr51-1753465816651594","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt490"},{"key":"bibr52-1753465816651594","unstructured":"Vibativ. (2015) Telavancin. Prescribing Information. San Francisco, CA: TheravanceBiopharma. http:\/\/www.vibativ.com (accessed 15 January 2015)."},{"key":"bibr53-1753465816651594","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1754"},{"key":"bibr54-1753465816651594","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ522"},{"key":"bibr55-1753465816651594","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-015-1847-6"},{"key":"bibr56-1753465816651594","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt022"}],"container-title":["Therapeutic Advances in Respiratory Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1753465816651594","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1753465816651594","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1753465816651594","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T18:38:29Z","timestamp":1740681509000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1753465816651594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,23]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["10.1177\/1753465816651594"],"URL":"https:\/\/doi.org\/10.1177\/1753465816651594","relation":{},"ISSN":["1753-4666","1753-4666"],"issn-type":[{"value":"1753-4666","type":"print"},{"value":"1753-4666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,23]]}}}